UBS O'Connor’s SpringWorks Therapeutics SWTX Stock Holding History

UBS O'Connor’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-25,000	Closed	-$13.8K	–	454
2024 Q4	$13.8K	Buy	+25,000	New	+$873K	﹤0.01%	388
2024 Q3	–	Sell	-20,000	Closed	-$24K	–	602
2024 Q2	$24K	Buy	+20,000	New	+$842K	﹤0.01%	473
2024 Q1	–	Sell	-30,000	Closed	-$99K	–	595
2023 Q4	$99K	Buy	+30,000	New	+$783K	﹤0.01%	412

Other funds holding SWTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

UBS O'Connor's SWTX Position: Q3 2025 in Review

UBS O'Connor sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 1,385,517 shares — an estimated $65.1M sold.

UBS O'Connor first reported a position in SWTX in Q1 2022 and held it in 14 quarters. The position peaked at $65.1M in Q2 2025. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

UBS O'Connor reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
UBS O'Connor sold 1,385,517 SpringWorks Therapeutics shares in Q3 2025, an estimated $65.1M.
UBS O'Connor first reported a position in SpringWorks Therapeutics in Q1 2022 and held it in 14 quarters.
UBS O'Connor's SpringWorks Therapeutics position peaked at $65.1M in Q2 2025.
3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.